The Expression of Bcl-2 and BID in Gastric Cancer Cells

Table 1

Bcl-2 and BID expression in gastric cancer cells depending on clinicopathological factors and Helicobacter pylori infection.

Variable	Bcl-2		𝑃	BID		𝑃
	(+)	(−)		(+)	(−)
	𝑛 (%)			𝑛 (%)
Protein expression	49 (55.7%)	39 (44.3%)		45 (53.6%)	39 (46.4%)
Age
<60	16 (48.5%)	17 (51.5%)	NS	16 (48.5%)	17 (51.5%)	NS
≥60	33 (60.0%)	22 (40.0%)		29 (56.9%)	22 (43.1%)
Sex
Female	16 (55.2%)	13 (44.8%)	NS	12 (44.4%)	15 (55.6%)	NS
Male	33 (55.9%)	26 (44.1%)		33 (57.9%)	24 (42.1%)
Depth of infiltration (pT)
pT1, T2	12 (40.0%)	18 (60.0%)	<0,05	11 (39.3%)	17 (60.7%)	NS
pT3, T4	37 (63.8%)	21 (36.2%)		34 (60.7%)	22 (39.3%)
Lauren’s classification
Intestinal type	42 (71.2%)	17 (37.8%)	<0,001	33 (60.0%)	22 (40.0%)	NS
Diffuse type	7 (25.0%)	21 (75.0%)		12 (42.9%)	16 (57.1%)
Malignancy grade (G)
2	28 (62.2%)	17 (37.8%)	NS	27 (62.8%)	16 (37.2%)	NS
3	21 (48.8%)	22 (51.2%)		18 (43.9%)	23 (56.1%)
Cancer location in the stomach
Upper 1/3	2 (33.3%)	4 (66.7%)	NS	3 (50.0%)	3 (50.0%)	NS
Middle 1/3	21 (55.3%)	17 (44.7%)		18 (50.0%)	18 (50.0%)
Lower 1/3	26 (59.1%)	18 (40.9%)		24 (57.1%)	18 (42.9%)
Bormann’s classification
1	0 (00.0%)	7 (100%)	<0,01	4 (57.1%)	3 (42.9%)	NS
2	15 (71.4%)	6 (28.6%)		6 (33.3%)	12 (66.7%)
3	26 (57.8%)	19 (42.2%)		28 (65.1%)	15 (34.9%)
4	8 (53.3%)	7 (46.7%)		7 (43.8%)	9 (56.3%)
Lymph node involvement
Present	19 (73.1%)	7 (26.9%)	<0,05	13 (52.0%)	12 (48.0%)	NS
Absent	30 (48.4%)	32 (51.6%)		32 (54.2%)	27 (45.8%)
H. pylori infection
Present	21 (51.2%)	20 (48.8%)	NS	20 (48.8%)	21 (51.2%)	NS
Absent	23 (62.2%)	14 (37.8%)		21 (61.8%)	13 (38.2%)

NS: nonsignificant.